DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Aptiom is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-seven patent family members in thirty countries.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.
Aptiom was eligible for patent challenges on November 8, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 21, 2026. This may change due to patent challenges or generic licensing.
There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (eslicarbazepine acetate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for APTIOM
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||61|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for APTIOM|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for APTIOM|
|DailyMed Link:||APTIOM at DailyMed|
Generic Entry Opportunity Date for APTIOM
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for APTIOM
Identify potential brand extensions & 505(b)(2) entrants
|Stanford University||Phase 4|
Pharmacology for APTIOM
|Mechanism of Action||Cytochrome P450 3A4 Inducers |
Cytochrome P450 2C19 Inhibitors
|Physiological Effect||Decreased Central Nervous System Disorganized Electrical Activity |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Sunovion Pharms Inc||APTIOM||eslicarbazepine acetate||TABLET;ORAL||022416-004||Nov 8, 2013||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Sunovion Pharms Inc||APTIOM||eslicarbazepine acetate||TABLET;ORAL||022416-003||Nov 8, 2013||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Sunovion Pharms Inc||APTIOM||eslicarbazepine acetate||TABLET;ORAL||022416-003||Nov 8, 2013||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|0751129||SPC027/2009||Ireland||Start Trial||SPC027/2009: 20091119, EXPIRES: 20210627|
|0751129||09C0040||France||Start Trial||PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|